'Egfr mutation' presentation slideshows

LUNG CANCER AND EGFR

1.61k views • 82 slides

Victor Cohen, MDCM, FRCPC Department of Oncology Segal Cancer Center

915 views • 62 slides

Patient Case 1

Patient Case 1. Patient Case 1: PET/CT Scan. Patient Case 1: Disease Stage. Techniques for Diagnosis of Lung Cancer. Use of EBUS Cytologic Material for Molecular Diagnosis of Lung Cancer. Histology in NSCLC. Lung Cancer Pathology: Non-Small Cell Carcinoma and Small Tissue Specimens.

943 views • 53 slides

1.41k views • 50 slides

1.28k views • 49 slides

New Strategies on Horizon

New Strategies on Horizon. Tony Mok MD Dept of Clinical Oncology The Chinse University of Hong Kong. Addressing the difference. TKI is forever. Novel Target. TKI is forever. 5cm. PR at 2cm. RECIST PD At 2.6cm. 0m. 6m. 12m. 18m. 5cm. PR at 2cm. Symptomatic PD at 4cm. 0m. 6m.

594 views • 48 slides

Fouad Al Dayel, MD, FRCPA, FRCPath Professor and Chairman

25 th IAP-Arab Division Conference 07-09 November 2013, Amman, Jordan. MOLECULAR PREDICTIVE. MARKERS OF LUNG CARCINOMA:. KFSH&RC EXPERIENCE. Fouad Al Dayel, MD, FRCPA, FRCPath Professor and Chairman Department of Pathology and Laboratory Medicine

866 views • 47 slides

Vera Hirsh, MD, FRCPC McGill University Health Centre Montreal, QC, CANADA

Clinical data on EGFR-TKIs and Overcoming Resistance in Metastatic NSCLC 2 nd Quebec Conference on Therapeutic Resistance in Cancer. Vera Hirsh, MD, FRCPC McGill University Health Centre Montreal, QC, CANADA. EGFR expression in human tumours. Tumours showing high EGFR expression.

536 views • 41 slides

Non-Small Cell Lung Cancer Year in Review 2012

655 views • 39 slides

Acquired Resistance Patient Forum

Combinations for Treating EGFR Acquired Resistance. Melissa L. Johnson, MD. Acquired Resistance Patient Forum. In ALK, ROS1 & EGFR Lung Cancers. September 6, 2014 | Boston. Combination Treatments for EGFR Acquired Resistance. Dx : EGFR+ lung cancer. Acquired Resistance.

620 views • 27 slides

Molecular Profiling and Patient Selection

339 views • 25 slides

Molecular Profiling and Patient Selection

406 views • 25 slides

????? EGFR ?????????????

????? EGFR ?????????????. ? ? ?????????? ??????. IPASS Study:Progression-free survival by EGFR mutation type (ITT population). Exon 19 deletion. L858R. Gefitinib (n=66) Carboplatin/paclitaxel (n=74). Gefitinib (n=64) Carboplatin/paclitaxel (n=47). 1.0. 1.0.

741 views • 24 slides

Biology of EGFR Mutations and Acquired Resistance to EGFR TKIs

362 views • 19 slides

314 views • 17 slides

322 views • 11 slides

Global Epidemiologic Variability of EGFR Mutation NSCLC

Global Epidemiologic Variability of EGFR Mutation NSCLC. Keunchil Park, MD, PhD Professor Division of Hematology/Oncology Department of Medicine Sungkyunkwan University School of Medicine Samsung Medical Center Seoul, Korea.

409 views • 8 slides

First-Line TKI Use in EGFR Mutation-Positive NSCLC

400 views • 8 slides

557 patients included in the ITT efficacy analysis 555 assessed for EGFR expression

1861 patients screened 1688 with tumors suitable for EGFR expression assessment. 321 excluded 183 did not meet inclusion criteria 79 refused to participate 59 other reasons. 1442 patients with EGFR-expressing tumors. 4 EGFR status unknown. 1125 randomly assigned ITT population.

194 views • 1 slides

EGFR Mutation

S-Table 1. Tang et al., BJC. NSCLC Cell Lines. SW900. H2122. H1975. H1437. H1838. H441. H520. H596. H661. H226. A549. EGFR Mutation. KRAS Mutation. Erlotinib Sensitivity. Histology. Gender.

614 views • 1 slides